DAXOR CORP 10-Q Summary: Period Ended June 30, 1995
Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 1995, for DAXOR Corporation. The company operates clinical laboratories, a blood bank, and a semen bank, while maintaining a significant portfolio of marketable securities. The company is currently engaged in multiple legal proceedings with the New York State Department of Health regarding its licensure.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1995 | Six Months Ended June 30, 1994 |
|---|---|---|
| Total Revenues | $2,333,830 | $2,344,873 |
| Operating Revenues | $933,593 | $953,908 |
| Net Income | $868,105 | $1,058,938 |
| Net Income Per Share | $0.17 | $0.21 |
| Cash from Operating Activities | $885,374 | $682,920 |
| Total Assets | $36,228,899 | $35,012,638 (Dec 31, 1994) |
| Total Liabilities | $5,442,736 | $5,813,458 (Dec 31, 1994) |
| Shareholders' Equity | $30,786,163 | $29,199,180 (Dec 31, 1994) |
| Loans Payable | $2,411,798 | $3,864,605 (Dec 31, 1994) |
Portfolio Highlights: Marketable securities are valued at $35,064,075 (fair value) with a cost basis of $26,813,190, resulting in net unrealized gains of $8,250,885. These gains are recorded in shareholders' equity.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased slightly by approximately 0.5% year-over-year for the six-month period, driven primarily by a reduction in gains from the sale of options and commodities ($7,090 in 1995 vs. $197,947 in 1994).
- Profitability: Net income decreased by approximately 18% to $868,105, largely due to the drop in investment gains and a 28% increase in Selling, General, and Administrative expenses ($829,996 vs. $646,076).
- Debt Reduction: Loans payable decreased significantly from $3,864,605 at year-end 1994 to $2,411,798 at June 30, 1995, following a $1,000,000 repayment of a bank loan.
- Share Repurchases: The company spent $1,220,800 on treasury stock purchases during the six-month period, increasing the value of treasury stock held.
Outlook, Risks, and Management Commentary
Liquidity and Capital: Management states the company has adequate resources to sustain its blood bank and develop its Blood Volume Analyzer (BVA-100). However, expanding blood banking operations on a nationwide basis would require additional capital.
Legal Contingencies: The company faces significant regulatory risks involving the New York State Department of Health:
- Licensure Challenges: Proceedings are ongoing regarding the denial of clinical laboratory and blood bank licensure for 1991-1993. An appeal is pending after a lower court denied the company's petition.
- Semen Bank Regulations: A hearing concluded in June 1995 regarding alleged violations of semen bank regulations; a decision is pending. The company is also challenging the constitutionality of these regulations.
- License Revocation: The company challenged a determination to revoke all licenses for its New York health care facilities. While a lower court denied the application, the company obtained an interim stay of the revocation pending appeal.
Investor Verification Checklist
- Verify the status of the interim stay regarding the revocation of New York health care facility licenses.
- Monitor the outcome of the pending administrative decision on semen bank regulation violations.
- Assess the sustainability of investment income, which comprised over 47% of total revenues for the six-month period.
- Review the impact of rising SG&A expenses on future operating margins.
- Confirm the company's ability to fund nationwide expansion without diluting shareholders, given current capital constraints.